C4 Therapeutics (CCCC) Leases (2019 - 2026)

C4 Therapeutics has reported Leases for 8 years, with the latest figure at $39.1 million in Q1 2026.

• For the quarter ending Q1 2026, Leases fell 30.05% year-over-year to $39.1 million; the trailing twelve-month figure through Mar 2026 stood at $39.1 million (down 30.05% YoY), and the FY2025 full-year result was $40.5 million, down 29.55% from the prior year.
• Leases for Q1 2026 stood at $39.1 million, down from $40.5 million in the prior quarter.
• The five-year high for Leases was $74.8 million in Q1 2022, with the low at $39.1 million in Q1 2026.
• Average Leases over 5 years is $60.4 million, with a median of $62.4 million recorded in 2024.
• Year-over-year, Leases soared 484.68% in 2022 and tumbled 30.05% in 2026.
• Tracing CCCC's Leases over 5 years: stood at $70.1 million in 2022, then dropped by 8.79% to $64.0 million in 2023, then decreased by 10.04% to $57.5 million in 2024, then fell by 29.55% to $40.5 million in 2025, then dropped by 3.56% to $39.1 million in 2026.
• The last three Leases figures came in at $39.1 million (Q1 2026), $40.5 million (Q4 2025), and $42.0 million (Q3 2025), per Business Quant data.

Peer Comparison